People
After Health and Human Services Secretary Alex Azar, a former executive with Eli Lilly, unveiled a pricing reform that would allow pharma companies to end the rebate system and pass those savings directly to consumers, leaders from across the pharma industry are offering early support for the proposal.
First Light Diagnostics announced the addition of Dr. Peter Kaspar to the company’s board of directors effective January 1, 2019.
Robert Mahley, founder and president of Gladstone Institutes, an internationally-recognized expert on heart disease, cholesterol metabolism and Alzheimer’s disease, is launching a biotech company to focus on Alzheimer’s disease. The company is called GABAeron.
MorphoSys AG announced the appointment of David R. Trexler as President and member of the Board of Directors of MorphoSys US Inc., effective February 6, 2019.
Gilead Sciences reported earnings per share profits for the fourth quarter of $1.44 per share, below analysts’ expectations of $1.70.
$250,000 in Vilcek Foundation Prizes awarded to Angelika Amon, Amit Choudhary, Jeanne Paz, and Mikhail Shapiro
Ultragenyx Pharmaceutical Inc. announced the appointment of Shehnaaz Suliman, M.D., to the company’s Board of Directors, effective January 30, 2019.
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, announced that Teijin’s board of directors has elected Ichiro Watanabe, currently corporate officer of the Teijin Group, as its next president.
Last week HHS floated a plan that would allow companies to pass rebates of 26 to 30 percent of a drug’s list price directly to patients in order to be reflected in what consumers pay at the pharmacy counter.
Sidley Austin LLP is pleased to announce that former European Medicines Agency Senior Legal Adviser Georgia Gavriilidou has joined the firm as counsel in its London office.
PRESS RELEASES